Therefore, the strategy of targeting KRAS to treat pancreatic cancer has been applied at different stages of KRAS molecular intracellular processes, such as anti-KRAS peptides and downstream signaling inhibitors [8,9]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.